Actinogen Medical Valuation
| ACW Stock | 0.03 0 3.85% |
Actinogen Medical seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Actinogen Medical from analyzing the firm fundamentals such as Return On Equity of -0.79, profit margin of (1.31) %, and Current Valuation of 74.1 M as well as examining its technical indicators and probability of bankruptcy.
Price Book 4.2257 | Enterprise Value 74.1 M | Enterprise Value Ebitda (9.95) | Price Sales 8.3659 | Forward PE 25.974 |
Overvalued
Today
Please note that Actinogen Medical's price fluctuation is out of control at this time. Calculation of the real value of Actinogen Medical is based on 3 months time horizon. Increasing Actinogen Medical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Actinogen Medical's intrinsic value may or may not be the same as its current market price of 0.03, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.027 | Real 0.025 | Hype 0.03 | Naive 0.0286 |
The intrinsic value of Actinogen Medical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Actinogen Medical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Actinogen Medical helps investors to forecast how Actinogen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Actinogen Medical more accurately as focusing exclusively on Actinogen Medical's fundamentals will not take into account other important factors: Actinogen Medical Cash |
|
Actinogen Medical Total Value Analysis
Actinogen Medical is presently anticipated to have takeover price of 74.1 M with market capitalization of 83.23 M, debt of 319.07 K, and cash on hands of 7.18 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Actinogen Medical fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
74.1 M | 83.23 M | 319.07 K | 7.18 M |
Actinogen Medical Investor Information
About 16.0% of the company shares are held by company insiders. The book value of Actinogen Medical was presently reported as 0.01. The company recorded a loss per share of 0.01. Actinogen Medical had not issued any dividends in recent years. The entity had 1:2 split on the 3rd of December 2013. Based on the analysis of Actinogen Medical's profitability, liquidity, and operating efficiency, Actinogen Medical is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Actinogen Medical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Actinogen Medical has an asset utilization ratio of 46.6 percent. This implies that the Company is making USD0.47 for each dollar of assets. An increasing asset utilization means that Actinogen Medical is more efficient with each dollar of assets it utilizes for everyday operations.Actinogen Medical Ownership Allocation
Actinogen Medical holds a total of 3.08 Billion outstanding shares. Actinogen Medical shows 15.6 percent of its outstanding shares held by insiders and 8.02 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Actinogen Medical Profitability Analysis
The company reported the revenue of 9.93 M. Net Loss for the year was (13.04 M) with profit before overhead, payroll, taxes, and interest of 4.89 M.About Actinogen Medical Valuation
The stock valuation mechanism determines Actinogen Medical's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Actinogen Medical based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Actinogen Medical. We calculate exposure to Actinogen Medical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Actinogen Medical's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 9.9 M | 10.4 M |
Additional Tools for Actinogen Stock Analysis
When running Actinogen Medical's price analysis, check to measure Actinogen Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actinogen Medical is operating at the current time. Most of Actinogen Medical's value examination focuses on studying past and present price action to predict the probability of Actinogen Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actinogen Medical's price. Additionally, you may evaluate how the addition of Actinogen Medical to your portfolios can decrease your overall portfolio volatility.